Claims for Patent: 10,086,006

Summary for Patent: 10,086,006

Title:	Method for improving drug treatments in mammals
Abstract:	An improved method for identifying the size, shape and duration of drug exposure necessary to improve drug treatment in a subject with a bacterial infection. In addition, an improved method for identification of new dosing strategies which optimize the probability of positive treatment outcomes in subjects using resistance inhibitory concentration (RIC), wherein the subject has a bacterial infection caused by a bacterium with a propensity for heteroresistance. Further, an improved method for decreasing the potential for on-therapy drug resistance by determining a patient's RIC prior to administration of fosfomycin treatment, wherein RIC is utilized to differentiate the parameter which is best related to the driver or index of fosfomycin efficacy for the resistant subpopulation present and the required inhibitory concentration of those mutants.
Inventor(s):	Paul G. Ambrose, Evelyn Ellis-Grosse
Assignee:	Meitheal Pharmaceuticals Inc
Application Number:	US15/136,704
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,086,006
Patent Claims:	1. A method for treating a subject with a bacterial infection that includes infection with a “resistant” mutant subpopulation of E. coli, the method comprising: a. obtaining a sample from a subject suffering from a bacterial infection; b. identifying the presence of a “resistant” mutant subpopulation of E. coli in said sample; c. administering fosfomycin to a subject according to an optimum dosing interval consistent with the resistance inhibitory concentration (RIC) of fosfomycin required to inhibit “resistant” mutant subpopulations of the E. coli identified in step b); wherein the bacterial density is effectively reduced and the fosfomycin-resistant subpopulation is inhibited. 2. A method for treating a subject with a bacterial infection that includes infection with a “resistant” mutant subpopulation selected from the group consisting of Enterobacter spp., Klebsiella oxytoca, Klebsiella pneumonia, Proteus mirabilis, Proteus vulgaris, and E. coli, the method comprising: a. obtaining a sample from a subject suffering from a bacterial infection; b. identifying the presence of the “resistant” mutant subpopulation in said sample; c. administering fosfomycin to a subject according to an optimum dosing interval consistent with the resistance inhibitory concentration (RIC) of fosfomycin required to inhibit the “resistant” mutant subpopulations identified in step b); wherein the bacterial density is effectively reduced and the fosfomycin-resistant subpopulation is inhibited. 3. The method of claim 1 or claim 2, wherein the dosing interval is once every six hours. 4. The method of claim 1 or claim 2, wherein the dosing interval is once every eight hours. 5. The method of claim 3, wherein the dose of fosfomycin is about 100 mg/kg. 6. The method of claim 4, wherein the dose of fosfomycin is about 100 mg/kg. 7. A method of treating an individual suffering from a bacterial infection, wherein the infection includes an antibiotic-resistant subpopulation selected from the group consisting of Enterobacter spp., Klebsiella oxytoca, Klebsiella pneumonia, Proteus mirabilis, Proteus vulgaris and E. coli, comprising: a. obtaining a sample from the subject suffering from the bacterial infection; b. confirming the presence of the antibiotic-resistant subpopulation in the sample from step a; c. administering an amount of fosfomycin based on an initial dosing interval using a resistance inhibitory concentration (RIC) necessary to inhibit the antibiotic-resistant subpopulation from step b; d. administering an amount of fosfomycin based on a subsequent dosing interval using a resistance inhibitory concentration (RIC) necessary to inhibit the antibiotic-resistant subpopulation from step b, wherein as the dosing interval decreases, the amount of bacterial killing increases, further wherein the antibiotic-resistant subpopulation is inhibited. 8. The method of claim 7, wherein the initial dosing interval is every eight hours and the subsequent dosing interval is every six hours. 9. The method of claim 8, wherein the dose of fosfomycin is about 100 mg/kg.